ICPT Intercept Pharmaceuticals Inc.

Intercept to Announce Second Quarter 2023 Financial Results on August 2, 2023

Intercept to Announce Second Quarter 2023 Financial Results on August 2, 2023

MORRISTOWN, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, will announce its second quarter 2023 financial results on Wednesday, August 2, 2023. The announcement will be followed by a conference call and audio webcast at 8:30 a.m. ET.

Participants can access the conference call live via webcast which will be available on the investor page of the company’s website at . Participants who wish to ask a question may register to receive dial-in numbers and a unique pin to join the call. While not required, it is recommended you join 10 minutes prior to the event's start. A replay of the call will be available on Intercept’s website following the completion of the call.

About Intercept     

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). For more information, please visit or connect with the Company on and .

Contact     

For more information about Intercept, please contact:

Investor inquiries: 

Media inquiries:



EN
26/07/2023

Underlying

ICPTIntercept Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Intercept Pharmaceuticals Inc.

 PRESS RELEASE
Free
ICPT Intercept Pharm...

Intercept Announces FDA Acceptance of Supplemental New Drug Applicatio...

Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBCPrecedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registriesFDA has assigned a PDUFA target action date of October 15, 2024 MORRISTOWN, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned...

February 29, 2024 1 EN
 PRESS RELEASE
Free
ICPT Intercept Pharm...

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA...

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 2023 Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% reduction from baseline in serum ALP (primary endpoint) Treatment-emergent adverse events were generally balan...

November 13, 2023 1 EN
 PRESS RELEASE
Free
ICPT Intercept Pharm...

Intercept Announces New Findings from Long-term Extension of Landmark ...

Intercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting® 2023 New analysis demonstrates the impact of OCA on achievement of GGT

November 10, 2023 1 EN
 PRESS RELEASE
Free
ICPT Intercept Pharm...

Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.

Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc. BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc. Following the completion of Alfasigma’s successful tender offer to purchase all outstanding shares of common stock of Intercept for USD 19.00 per share, net to the seller thereof in cash, without interest, less any applicable withh...

November 8, 2023 1 EN
 PRESS RELEASE
Free
ICPT Intercept Pharm...

Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in...

Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases Proposed all-cash acquisition will materially expand Alfasigma’s portfolio in gastroenterology and hepatology and its presence in the U.S. marketTransaction price represents an 82% premium to Intercept’s closing price on September 25, 2023Alfasigma adds Ocaliva®, the only FDA approved second-line treatment for PBC, a progressive autoimmune disease affecting the liver, which generated revenue of $152 million in 1H 2023Strengt...

September 26, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch